​

Guardant Health (GH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GH Stock Forecast

Guardant Health (GH) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $52.00, with a high of $52.00 and a low of $52.00. This represents a 15.63% increase from the last price of $44.97.

$15 $23 $31 $39 $47 $55 High: $52 Avg: $52 Low: $52 Last Closed Price: $44.97

GH Stock Rating

Guardant Health stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (96.00%), 0 Hold (0.00%), 1 Sell (4.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 1 24 Strong Sell Sell Hold Buy Strong Buy

GH Price Target Upside V Benchmarks

TypeNameUpside
StockGuardant Health15.63%
SectorHealthcare Stocks 35.25%
IndustryDiagnostics & Research Stocks46.62%

Price Target Trends

1M3M12M
# Anlaysts-111
Avg Price Target-$52.00$38.91
Last Closing Price$44.97$44.97$44.97
Upside/Downside-15.63%-13.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 256142--22
Mar, 256142--22
Feb, 257142--23
Jan, 258142--24
Dec, 247141--22
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 05, 2025Morgan Stanley$52.00$42.6621.89%15.63%
Aug 21, 2024Dan LeonardUBS$40.00$27.6844.51%-11.05%
Aug 08, 2024Bill BonelloCraig-Hallum$37.00$31.3717.95%-17.72%
Aug 08, 2024Tycho PetersonJefferies$40.00$33.9617.79%-11.05%
Jul 29, 2024Mark MassaroBTIG$50.00$35.2841.72%11.19%
Jun 28, 2024Subbu NambiGuggenheim$36.00$28.8824.65%-19.95%
Jun 04, 2024Kyle MiksonCanaccord Genuity$38.00$27.4138.64%-15.50%
Jun 03, 2024Tycho PetersonJefferies$32.00$27.1018.08%-28.84%
May 23, 2024Mark MassaroBTIG$45.00$22.5199.91%0.07%
May 22, 2024Kyle MiksonCanaccord Genuity$30.00$23.0130.38%-33.29%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 05, 2025Morgan StanleyOverweightOverweighthold
Jan 10, 2025BernsteinOutperformOutperformhold
Aug 21, 2024UBSBuyBuyhold
Aug 13, 2024Piper SandlerNeutralNeutralhold
Aug 08, 2024Cowen & Co.BuyBuyhold
Aug 08, 2024Craig-HallumBuyBuyhold
Aug 08, 2024JefferiesBuyBuyhold
Jul 29, 2024BTIGBuyBuyhold
Jul 29, 2024William BlairOutperformOutperformhold
Jun 28, 2024StephensBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.53$-3.80$-6.41$-4.28$-3.56----
Avg Forecast$-2.18$-4.26$-6.45$-3.58$-3.41$-2.90$-2.46$-2.32$-2.13
High Forecast$-2.10$-4.11$-6.26$-3.49$-3.32$-2.26$-1.18$-0.24$-2.04
Low Forecast$-2.23$-4.36$-6.80$-3.68$-3.50$-3.73$-2.99$-3.72$-2.29
Surprise %16.06%-10.80%-0.62%19.55%4.40%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$286.73M$373.65M$449.54M$563.95M$739.02M----
Avg Forecast$284.99M$364.29M$446.54M$558.07M$729.04M$846.27M$1.02B$1.23B$1.46B
High Forecast$289.97M$370.66M$464.85M$589.10M$729.24M$868.09M$1.02B$1.24B$1.54B
Low Forecast$277.20M$354.33M$435.97M$538.39M$728.83M$819.82M$1.02B$1.22B$1.41B
Surprise %0.61%2.57%0.67%1.05%1.37%----

Net Income Forecast

$-700M $-560M $-420M $-280M $-140M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-246.28M$-384.77M$-654.59M$-479.45M$-436.37M----
Avg Forecast$-221.25M$-372.37M$-508.71M$-479.45M$-382.22M$-364.59M$-312.67M$-168.64M$-238.87M
High Forecast$-177.00M$-297.90M$-406.97M$-383.56M$-372.11M$-252.82M$-132.14M$-27.21M$-227.92M
Low Forecast$-265.50M$-446.85M$-610.45M$-575.34M$-392.33M$-417.56M$-334.31M$-416.51M$-256.14M
Surprise %11.31%3.33%28.68%-14.17%----

GH Forecast FAQ

Is Guardant Health stock a buy?

Guardant Health stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 0 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Guardant Health is a favorable investment for most analysts.

What is Guardant Health's price target?

Guardant Health's price target, set by 25 Wall Street analysts, averages $52 over the next 12 months. The price target range spans from $52 at the low end to $52 at the high end, suggesting a potential 15.63% change from the previous closing price of $44.97.

How does Guardant Health stock forecast compare to its benchmarks?

Guardant Health's stock forecast shows a 15.63% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the diagnostics & research stocks industry (46.62%).

What is the breakdown of analyst ratings for Guardant Health over the past three months?

  • April 2025: 27.27% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 27.27% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 30.43% Strong Buy, 60.87% Buy, 8.70% Hold, 0% Sell, 0% Strong Sell.

What is Guardant Health’s EPS forecast?

Guardant Health's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.9, marking a -18.54% decrease from the reported $-3.56 in 2024. Estimates for the following years are $-2.46 in 2026, $-2.32 in 2027, and $-2.13 in 2028.

What is Guardant Health’s revenue forecast?

Guardant Health's average annual revenue forecast for its fiscal year ending in December 2025 is $846.27M, reflecting a 14.51% increase from the reported $739.02M in 2024. The forecast for 2026 is $1.02B, followed by $1.23B for 2027, and $1.46B for 2028.

What is Guardant Health’s net income forecast?

Guardant Health's net income forecast for the fiscal year ending in December 2025 stands at $-365M, representing a -16.45% decrease from the reported $-436M in 2024. Projections indicate $-313M in 2026, $-169M in 2027, and $-239M in 2028.